These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38982006)

  • 21. Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections.
    Agarwal P; Craig JP; Krösser S; Eickhoff K; Swift S; Rupenthal ID
    Eur J Pharm Biopharm; 2019 Sep; 142():83-91. PubMed ID: 31195132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics.
    Singh A; Ahmad I; Ahmad S; Iqbal Z; Ahmad FJ
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1524-36. PubMed ID: 26902951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Azithromycin cationic non-lecithoid nano/microparticles improve bioavailability and targeting efficiency.
    Zhong M; Feng Y; Liao H; Hu X; Wan S; Zhu B; Zhang M; Xiong H; Zhou Y; Zhang J
    Pharm Res; 2014 Oct; 31(10):2857-67. PubMed ID: 25208873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vitro Anti-inflammatory and Antimicrobial Activities of Azithromycin After Loaded in Chitosan- and Tween 20-Based Oil-in-Water Macroemulsion for Acne Management.
    Shunmugaperumal T; Kaur V
    AAPS PharmSciTech; 2016 Jun; 17(3):700-9. PubMed ID: 26314246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Chitosan-Coated Niosomal Formulation for Improved Management of Bacterial Conjunctivitis: A Highly Permeable and Efficient Ocular Nanocarrier for Azithromycin.
    Eid HM; Naguib IA; Alsantali RI; Alsalahat I; Hegazy AM
    J Pharm Sci; 2021 Aug; 110(8):3027-3036. PubMed ID: 33940026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages.
    Togami K; Chono S; Morimoto K
    Biopharm Drug Dispos; 2011 Oct; 32(7):389-97. PubMed ID: 21812004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats.
    Ohtani H; Taninaka C; Hanada E; Kotaki H; Sato H; Sawada Y; Iga T
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2630-7. PubMed ID: 10991836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
    Soni K; Rizwanullah M; Kohli K
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis.
    Cohen R; Reinert P; De La Rocque F; Levy C; Boucherat M; Robert M; Navel M; Brahimi N; Deforche D; Palestro B; Bingen E
    Pediatr Infect Dis J; 2002 Apr; 21(4):297-303. PubMed ID: 12075760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the Microbiological Efficacy of a Single 2-Gram Dose of Extended-Release Azithromycin by Population Pharmacokinetics and Simulation in Japanese Patients with Gonococcal Urethritis.
    Soda M; Ito S; Matsumaru N; Nakamura S; Nagase I; Takahashi H; Ohno Y; Yasuda M; Yamamoto M; Tsukamoto K; Itoh Y; Deguchi T; Kitaichi K
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
    Dudhipala N; Janga KY; Gorre T
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of in vitro ADME properties and pharmacokinetics of azithromycin and selected 15-membered ring macrolides in rodents.
    Milić A; Mihaljević VB; Ralić J; Bokulić A; Nožinić D; Tavčar B; Mildner B; Munić V; Malnar I; Padovan J
    Eur J Drug Metab Pharmacokinet; 2014 Dec; 39(4):263-76. PubMed ID: 24114177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precisely Fabricated Sulpiride-Loaded Nanolipospheres with Ameliorated Oral Bioavailability and Antidepressant Activity.
    Mohyeldin SM; Samy WM; Ragab D; Abdelmonsif DA; Aly RG; Elgindy NA
    Int J Nanomedicine; 2021; 16():2013-2044. PubMed ID: 33727812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioequivalence study of two azithromycin formulations in healthy subjects.
    Setiawati E; Deniati SH; Yunaidi DA; Handayani LR; Harinanto G; Santoso ID; Sari AP; Rimainar A
    Arzneimittelforschung; 2009; 59(9):471-5. PubMed ID: 19856795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and optimization of controlled release bioerodable anti infective ophthalmic insert.
    Thakur R; Swami G; Rahman M
    Curr Drug Deliv; 2014; 11(1):2-10. PubMed ID: 22283654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime.
    Imran M; Shah MR; Ullah F; Ullah S; Elhissi AM; Nawaz W; Ahmad F; Sadiq A; Ali I
    Int J Pharm; 2016 May; 505(1-2):122-32. PubMed ID: 27050867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study.
    Radwan SE; Sokar MS; Abdelmonsif DA; El-Kamel AH
    Int J Pharm; 2017 Jun; 526(1-2):366-379. PubMed ID: 28487189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of acetazolamide ocular permeation using ascorbyl laurate nanostructures as drug delivery system.
    Tártara LI; Quinteros DA; Saino V; Allemandi DA; Palma SD
    J Ocul Pharmacol Ther; 2012 Apr; 28(2):102-9. PubMed ID: 22060001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study to enhance the oral bioavailability of s-adenosyl-l-methionine (SAMe): SLN and SLN nanocomposite particles.
    Amasya G; Ergin AD; Erkan Cakirci O; Ozçelikay AT; Sezgin Bayindir Z; Yuksel N
    Chem Phys Lipids; 2021 Jul; 237():105086. PubMed ID: 33930379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.